AI Engines For more Details: Perplexity Kagi Labs You
Alcohol Dependence: Naltrexone is approved for the treatment of alcohol dependence. It works by blocking the effects of endorphins, which are natural substances in the body that produce feelings of pleasure and well-being. By blocking these effects, naltrexone reduces the craving for alcohol and decreases the likelihood of relapse in individuals who have stopped drinking.
Opioid Dependence: Naltrexone is also used in the treatment of opioid dependence. It blocks the effects of opioids by occupying opioid receptors in the brain, thereby preventing the euphoric effects of opioids such as heroin, morphine, and oxycodone. Naltrexone is typically used in individuals who have completed detoxification and are motivated to remain abstinent from opioids.
Combination Therapy: Naltrexone is sometimes used in combination with other medications, such as bupropion, in the treatment of obesity. The combination medication, known as Contrave, works by reducing food cravings and appetite, thereby aiding in weight loss.
Autoimmune Diseases: There is ongoing research investigating the use of naltrexone in the treatment of certain autoimmune diseases, such as multiple sclerosis (MS) and Crohn's disease. Some studies suggest that low-dose naltrexone (LDN) may modulate the immune system and reduce inflammation, potentially offering benefits in the management of these conditions. However, further research is needed to determine its efficacy and safety in autoimmune diseases.
Other Conditions: Naltrexone is being studied for its potential efficacy in other conditions, such as fibromyalgia, chronic pain, and certain psychiatric disorders. While some preliminary research suggests possible benefits, more robust clinical trials are needed to establish its effectiveness and safety in these conditions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.2 | 0.5 |
| ADHD | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.9 | -0.5 |
| Allergies | 0.3 | 0.6 | -1 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 0.7 | 1.1 | -0.57 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 0.9 | 0.9 | 0 |
| Anorexia Nervosa | 0.3 | 0.9 | -2 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 1.3 | 0.6 | 1.17 |
| Atherosclerosis | 0.6 | 0.6 | |
| Atrial fibrillation | 0.9 | 0.3 | 2 |
| Autism | 1.1 | 1.3 | -0.18 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 0.3 | 0.3 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 1 | 0.3 | 2.33 |
| Celiac Disease | 0.6 | 0.6 | 0 |
| Cerebral Palsy | 0.6 | 0.3 | 1 |
| Chronic Fatigue Syndrome | 0.9 | 0.6 | 0.5 |
| Chronic Kidney Disease | 0.5 | 0.5 | 0 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.9 | 0.33 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
| Cognitive Function | 0.6 | 0.3 | 1 |
| Colorectal Cancer | 2.2 | 0.3 | 6.33 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.3 | 0.3 | 0 |
| COVID-19 | 1.1 | 1 | 0.1 |
| Crohn's Disease | 1 | 1 | 0 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.1 | 0.6 | -5 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 1.8 | 0.9 | 1 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.4 | 0.5 |
| Endometriosis | 0.6 | 0.3 | 1 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.9 | 0.3 | 2 |
| erectile dysfunction | 0.8 | 0.8 | |
| Fibromyalgia | 0.2 | 0.3 | -0.5 |
| Functional constipation / chronic idiopathic constipation | 0.9 | 0.5 | 0.8 |
| gallstone disease (gsd) | 0.3 | -0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.6 | -0.5 |
| Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.8 | 0.8 | |
| Graves' disease | 0.3 | 0.6 | -1 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 1 | 0.3 | 2.33 |
| Hashimoto's thyroiditis | 0.8 | 0.8 | 0 |
| Heart Failure | 0.8 | 0.8 | |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| hyperglycemia | 0.1 | 0.3 | -2 |
| hypertension (High Blood Pressure | 1.1 | 0.7 | 0.57 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.9 | 0.2 | 3.5 |
| Inflammatory Bowel Disease | 1.3 | 1.2 | 0.08 |
| Insomnia | 0.7 | 0.9 | -0.29 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 0.9 | 0.9 | 0 |
| ischemic stroke | 0.6 | 0.3 | 1 |
| Liver Cirrhosis | 1 | 0.9 | 0.11 |
| Long COVID | 1.4 | 1 | 0.4 |
| Low bone mineral density | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.4 | 0.4 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 0.9 | 0.9 | 0 |
| Mood Disorders | 1.7 | 0.9 | 0.89 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 1.2 | 0.7 | 0.71 |
| Multiple system atrophy (MSA) | 0.6 | 0.6 | |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.6 | -0.6 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 0.6 | 1.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.4 | 1.3 | 0.08 |
| obsessive-compulsive disorder | 0.9 | 0.8 | 0.13 |
| Osteoarthritis | 0.8 | 0.6 | 0.33 |
| Osteoporosis | 0.3 | 0.6 | -1 |
| pancreatic cancer | 0.4 | 0.3 | 0.33 |
| Parkinson's Disease | 0.9 | 1.4 | -0.56 |
| Polycystic ovary syndrome | 0.9 | 0.6 | 0.5 |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 1.4 | 1.4 | |
| Psoriasis | 0.3 | 0.3 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1 | 0.6 | 0.67 |
| Rosacea | 0.2 | 0.2 | |
| Schizophrenia | 1.2 | 0.6 | 1 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.3 | 0.3 | 0 |
| Sleep Apnea | 0.6 | 0.3 | 1 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.3 | 1 |
| Systemic Lupus Erythematosus | 0.9 | 0.3 | 2 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 0.6 | 0.9 | -0.5 |
| Type 2 Diabetes | 0.9 | 0.9 | 0 |
| Ulcerative colitis | 1.2 | 0.3 | 3 |
| Unhealthy Ageing | 1.2 | 1.2 | |
| Vitiligo | 0.9 | 0.9 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
